The company have advised that they will not be pursuing a licensing application for NGR-TNF from the European Medicines Authority for this indication at this time.
| Status | Suspended |
| Decision | Selected |
| Process | STA pre-2018 |
| ID number | 655 |
Project Team
| Project lead | Marcia Miller |
Email enquiries
- If you have any queries please email TAcommA@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 05 July 2017 | Suspended. The company have advised that they will not be pursuing a licensing application for NGR-TNF from the European Medicines Authority for this indication at this time. |
| 05 July 2017 | The Department of Health has asked NICE to conduct a Single Technology Appraisal of NGR-TNF for previously treated advanced malignant pleural Mesothelioma. However, the company have advised that they will not be pursuing a licensing application for NGR-TNF from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme. As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes |
| 21 April 2017 | Referral |
| 21 April 2017 | In progress. Topic referred |
For further information on our processes and methods, please see our CHTE processes and methods manual